BG107482A - Лекарствено средство за имунотерапия на злокачествени тумори - Google Patents
Лекарствено средство за имунотерапия на злокачествени тумори Download PDFInfo
- Publication number
- BG107482A BG107482A BG107482A BG10748203A BG107482A BG 107482 A BG107482 A BG 107482A BG 107482 A BG107482 A BG 107482A BG 10748203 A BG10748203 A BG 10748203A BG 107482 A BG107482 A BG 107482A
- Authority
- BG
- Bulgaria
- Prior art keywords
- tumor
- dendritic cells
- cells
- cell suspension
- induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 238000009169 immunotherapy Methods 0.000 title abstract description 7
- 201000011510 cancer Diseases 0.000 title description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 210000004443 dendritic cell Anatomy 0.000 claims description 27
- 210000004881 tumor cell Anatomy 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- 239000006285 cell suspension Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000013592 cell lysate Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 9
- 210000001616 monocyte Anatomy 0.000 claims description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 claims description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 6
- 102000004388 Interleukin-4 Human genes 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 229960003130 interferon gamma Drugs 0.000 claims description 5
- 230000035800 maturation Effects 0.000 claims description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- 230000001464 adherent effect Effects 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 4
- 102000007474 Multiprotein Complexes Human genes 0.000 claims description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 230000022534 cell killing Effects 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000000877 morphologic effect Effects 0.000 claims description 2
- 230000006855 networking Effects 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000002255 vaccination Methods 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 23
- 239000002609 medium Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000732 tissue residue Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00116362 | 2000-07-28 | ||
| PCT/EP2001/008455 WO2002009745A1 (de) | 2000-07-28 | 2001-07-21 | Arzneimittel zur immuntherapie maligner tumoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107482A true BG107482A (bg) | 2003-11-28 |
Family
ID=8169380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107482A Pending BG107482A (bg) | 2000-07-28 | 2003-01-21 | Лекарствено средство за имунотерапия на злокачествени тумори |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030129206A1 (no) |
| EP (1) | EP1305041B1 (no) |
| JP (1) | JP2004505058A (no) |
| AT (1) | ATE330626T1 (no) |
| AU (1) | AU2001279775A1 (no) |
| BG (1) | BG107482A (no) |
| CA (1) | CA2417374A1 (no) |
| CY (1) | CY1105179T1 (no) |
| CZ (1) | CZ299669B6 (no) |
| DE (1) | DE50110274D1 (no) |
| DK (1) | DK1305041T3 (no) |
| ES (1) | ES2267800T3 (no) |
| HK (1) | HK1055562A1 (no) |
| HU (1) | HUP0300772A3 (no) |
| NO (1) | NO20030420L (no) |
| PL (1) | PL358675A1 (no) |
| PT (1) | PT1305041E (no) |
| SI (1) | SI1305041T1 (no) |
| SK (1) | SK822003A3 (no) |
| WO (1) | WO2002009745A1 (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211971A1 (en) * | 2001-09-17 | 2003-11-13 | Srivastava Pramod K. | Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins |
| RU2324493C2 (ru) * | 2003-02-20 | 2008-05-20 | Юниверсити Оф Коннектикут Хелт Сентер | Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
| EP1974742A1 (en) * | 2007-03-29 | 2008-10-01 | LipoNova AG | A method for improving the manufacturing process of a tumour vaccine |
| AU2010268367B2 (en) | 2009-07-02 | 2016-10-20 | Ith Immune Therapy Holdings Ab | Exosome based treatment of cancer |
| CN105807053B (zh) | 2016-04-15 | 2019-04-02 | 苏州药明康德新药开发股份有限公司 | 一种肿瘤解离试剂在流式细胞检测中的应用 |
| ES2908885T3 (es) | 2017-07-05 | 2022-05-04 | Vcc Medical Deutschland Gmbh | Método para fabricar una vacuna tumoral |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077519A (en) * | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
| DE19633731A1 (de) * | 1996-08-21 | 1998-02-26 | Johann Hinrich Prof Dr Peters | Hybridzellen zur Steigerung der Immunogenität von Tumorzellen |
| AU2872199A (en) * | 1998-02-20 | 1999-09-06 | Rockefeller University, The | Apoptotic cell-mediated antigen presentation to dendritic cells |
| DE19812004A1 (de) * | 1998-03-19 | 1999-09-30 | Forschungszentrum Juelich Gmbh | Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung |
| WO1999047687A1 (en) * | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Enhanced anti-tumor immunity |
| DE69939821D1 (de) * | 1998-04-02 | 2008-12-11 | Univ California | Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten |
| US6045990A (en) * | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
-
2001
- 2001-07-21 DK DK01958002T patent/DK1305041T3/da active
- 2001-07-21 US US09/926,630 patent/US20030129206A1/en not_active Abandoned
- 2001-07-21 ES ES01958002T patent/ES2267800T3/es not_active Expired - Lifetime
- 2001-07-21 SK SK82-2003A patent/SK822003A3/sk unknown
- 2001-07-21 AU AU2001279775A patent/AU2001279775A1/en not_active Abandoned
- 2001-07-21 SI SI200130618T patent/SI1305041T1/sl unknown
- 2001-07-21 DE DE50110274T patent/DE50110274D1/de not_active Expired - Fee Related
- 2001-07-21 AT AT01958002T patent/ATE330626T1/de not_active IP Right Cessation
- 2001-07-21 PL PL01358675A patent/PL358675A1/xx unknown
- 2001-07-21 EP EP01958002A patent/EP1305041B1/de not_active Expired - Lifetime
- 2001-07-21 CA CA002417374A patent/CA2417374A1/en not_active Abandoned
- 2001-07-21 WO PCT/EP2001/008455 patent/WO2002009745A1/de active IP Right Grant
- 2001-07-21 PT PT01958002T patent/PT1305041E/pt unknown
- 2001-07-21 CZ CZ20030179A patent/CZ299669B6/cs not_active IP Right Cessation
- 2001-07-21 JP JP2002515298A patent/JP2004505058A/ja not_active Abandoned
- 2001-07-21 HU HU0300772A patent/HUP0300772A3/hu unknown
-
2003
- 2003-01-21 BG BG107482A patent/BG107482A/bg active Pending
- 2003-01-27 NO NO20030420A patent/NO20030420L/no not_active Application Discontinuation
- 2003-10-27 HK HK03107742A patent/HK1055562A1/xx not_active IP Right Cessation
-
2006
- 2006-08-29 CY CY20061101216T patent/CY1105179T1/el unknown
- 2006-11-06 US US11/593,132 patent/US20070134275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20030420D0 (no) | 2003-01-27 |
| AU2001279775A1 (en) | 2002-02-13 |
| PL358675A1 (en) | 2004-08-09 |
| CZ299669B6 (cs) | 2008-10-08 |
| CZ2003179A3 (cs) | 2004-01-14 |
| PT1305041E (pt) | 2006-09-29 |
| HUP0300772A3 (en) | 2005-11-28 |
| CY1105179T1 (el) | 2010-03-03 |
| HK1055562A1 (en) | 2004-01-16 |
| SK822003A3 (en) | 2004-05-04 |
| CA2417374A1 (en) | 2003-01-27 |
| US20070134275A1 (en) | 2007-06-14 |
| NO20030420L (no) | 2003-01-27 |
| EP1305041A1 (de) | 2003-05-02 |
| DE50110274D1 (de) | 2006-08-03 |
| JP2004505058A (ja) | 2004-02-19 |
| WO2002009745A1 (de) | 2002-02-07 |
| US20030129206A1 (en) | 2003-07-10 |
| DK1305041T3 (da) | 2006-10-23 |
| ES2267800T3 (es) | 2007-03-16 |
| HUP0300772A2 (en) | 2003-08-28 |
| ATE330626T1 (de) | 2006-07-15 |
| EP1305041B1 (de) | 2006-06-21 |
| SI1305041T1 (sl) | 2006-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5986196B2 (ja) | 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法 | |
| US9694059B2 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
| JPH11501656A (ja) | 腫瘍を処置する方法 | |
| JP2005515781A (ja) | 機能樹状細胞への単球の分化を誘導するための方法およびかかる樹状細胞を含む免疫療法組成物 | |
| JP6235085B2 (ja) | 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法 | |
| US20080213895A1 (en) | Method for culturing dendritic cells (DC) and cytokine-induced killer cells (D-CIK) and applications thereof | |
| CN106943432B (zh) | 一种脐带间充质干细胞来源的外泌体及其在制备治疗肝癌药物中的应用 | |
| RU2484134C2 (ru) | Клеточные линии, содержащие их композиции для лечения меланом, способы получения композиций и способы лечения | |
| US20070134275A1 (en) | Medicaments for the immunotherapy of malignant tumors | |
| Liu et al. | Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects | |
| EP1078043A1 (en) | New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines | |
| CN111117964B (zh) | 一种肿瘤来源外泌体及其制备方法和用途 | |
| CN108642013A (zh) | 一种从脐带血中分离cd34造血干细胞扩大培养后大规模诱导制备树突状细胞方法 | |
| JP2006124383A (ja) | 樹状細胞活性化剤 | |
| Okuzawa et al. | PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro | |
| Xie et al. | Inhibitory effects of a dendritic cell vaccine loaded with radiation-induced apoptotic tumor cells on tumor cell antigens in mouse bladder cancer | |
| JP5807769B2 (ja) | 頭頚部癌の治療に用いる、腫瘍栄養動脈に投与される抗癌細胞組成物の使用 | |
| KR100562274B1 (ko) | 수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물 | |
| KR102698871B1 (ko) | 수지상 세포, 자연 살해 세포 및 세포 독성 t 세포를 포함하는 암의 예방 또는 치료용 생물학적 조성물 | |
| WO2009008666A2 (en) | Autologous dendritic cell mediated by photodynamic therapy having the ability to suppress the growth of tumor | |
| CN116370496A (zh) | 胀果甘草多糖在制备治疗和/或预防肝癌的药物中的应用 | |
| EP1577381A1 (en) | Tumor/B-cell hybrid cells and uses thereof | |
| CZ22766U1 (cs) | Sada pro přípravu protínádorové vakcíny a protinádorová vakcína | |
| EA011421B1 (ru) | Способ получения противоопухолевой вакцины |